A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients - Contacts and Locations

Home

A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients

This study has been completed.

Study NCT00703391. Last updated on November 3, 2008. Information provided by AstraZeneca

Please refer to this study by its ClinicalTrials.gov identifier: NCT00703391

Locations

Sponsors and Collaborators

AstraZeneca

Investigators


Principal Investigator:	Kristina Panke	Parexel International GmbhH (CRO)